Page last updated: 2024-12-05

pirinixic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pirinixic acid: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5694
CHEMBL ID295416
CHEBI ID32509
SCHEMBL ID293161
MeSH IDM0048640

Synonyms (160)

Synonym
CBIOL_001856
HMS3267N11
BRD-K01902415-001-02-6
2-[4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl]sulfanylacetic acid
gtpl2666
NCI60_002666
pirnixic acid
({4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}thio)acetic acid
pirinixic acid
[4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid
acetic acid,3-xylidino)-2-pyrimidinyl]thio]-
50892-23-4
NSC310038 ,
nsc-310038
wy-14,643
acetic acid,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]-
((4-chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)acetic acid
((4-chloro-6-(2,3-dimethylanilino)-2-pyrimidinyl)thio)acetic acid
(4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid
({4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}sulfanyl)acetic acid
CHEBI:32509 ,
tocris-1312
NCGC00025107-01
BIO1_000631
BIO2_000260
BIO1_000142
BIO1_001120
BIO2_000740
CMAP_000028
dtxsid4020290 ,
NCGC00014702
SPECTRUM5_001947
IDI1_034010
acidum pirinixicum [inn-latin]
acide pirinixique [inn-french]
pirinixic acid [inn]
wyeth 14,643
acetic acid, ((4-chloro-6-((2,3-dimethylphenyl)amino)-2-pyrimidinyl)thio)-
ccris 133
wy 14643
acetic acid, ((4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thio)-
nsc 310038
((4-chloro-6-(2,3-xylidino)-2-pyrimidinyl)thio)acetic acid
brn 0759945
acido pirinixico [inn-spanish]
wy14643
wy-14643 ,
NCI310038
NCGC00025107-02
NCGC00025107-05
NCGC00025107-04
NCGC00025107-06
NCGC00025107-07
KBIO2_004921
KBIO3_002832
KBIO2_000260
KBIO3_000520
KBIOSS_000260
KBIO2_007489
KBIOSS_002356
KBIOGR_000260
KBIOGR_002353
KBIO2_005396
KBIO2_002828
KBIO3_000519
KBIO2_002353
NCISTRUC1_001774
NCISTRUC2_001509
SPECTRUM1505106
(4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid
BSPBIO_001540
NCGC00025107-08
NCGC00025107-03
chembl295416 ,
2-({4-chloro-6-[(2,3-dimethylphenyl)amino]pyrimidin-2-yl}sulfanyl)acetic acid
bdbm24566
jmc515449 compound 1
wyeth-14,643
HMS1989M22
BML2-E12
HMS1361M22
HMS1791M22
SR-01000597401-4
sr-01000597401
2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanylacetic acid
NCGC00014702-03
NCGC00259158-01
NCGC00254449-01
tox21_201609
tox21_300634
dtxcid00290
cas-50892-23-4
tox21_110058
smr001798898
MLS004773935
wy-14643 (pirinixic acid)
CCG-37145
NCGC00014702-09
NCGC00014702-06
NCGC00014702-11
NCGC00014702-08
NCGC00014702-12
NCGC00014702-10
NCGC00014702-05
NCGC00014702-07
NCGC00014702-04
NCGC00014702-02
wy1 ,
5-25-12-00458 (beilstein handbook reference)
unii-86c4mrt55a
acido pirinixico
86c4mrt55a ,
acide pirinixique
acidum pirinixicum
hsdb 8056
FT-0602973
AKOS015902283
S8029
SCHEMBL293161
AM81246
acetic acid, 2-[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]-
tox21_110058_1
NCGC00014702-15
ES-0025
[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]aceticacid
CS-4661
[4-chloro-6-(2,3-xylidino)-2-pyrimidinyl-thio]-acetic acid
[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]acetic acid
[4-chloro-6-(2,3-dimethyl-phenylamino)-pyrimidin-2-ylsulfanyl]-acetic acid
([4-chloro-6-(2,3-dimethylanilino)-2-pyrimidinyl]sulfanyl)acetic acid #
AC-31440
HY-16995
HMS3402M22
HMS3649C12
mfcd00191335
SR-01000597401-1
SR-01000597401-3
HMS3653N21
acetic acid, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]-
NCGC00014702-17
SW203787-2
A918541
wy14643 (pirinixic acid)
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)acetic acid
BCP21201
[[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio]-acetic acid
wy 14643 (pirinixic acid)
EX-A2258
wy-14643; pirinixic acid
HMS3676G06
2-((4-chloro-6-((2,3-dimethylphenyl)amino)pyrimidin-2-yl)thio)acetic acid
SR-01000597401-6
HMS3412G06
Q7198008
BRD-K01902415-001-03-4
SB19568
pirinixic-acid
C75388
4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid pirinixic acid
2-((4-chloro-6-((2,3-dimethylphenyl)amino)pyrimidin-2-yl)thio)aceticacid

Research Excerpts

Overview

Pirinixic acid is an agonist of the peroxisome proliferator-activated receptor (PPAR) subtype alpha. It exhibits beneficial effects in various inflammation-related processes in a slow, long-termed fashion.

ExcerptReferenceRelevance
"Pirinixic acid is a typical fatty acid mimetic and was developed as synthetic antihyperlipidemic agent. "( Pirinixic acids: flexible fatty acid mimetics with various biological activities.
Merk, D; Schubert-Zsilavecz, M; Steinhilber, D; Werz, O; Zettl, M, 2015
)
3.3
"Pirinixic acid (Wy-14,643) is an agonist of the peroxisome proliferator-activated receptor (PPAR) subtype alpha exhibiting beneficial effects in various inflammation-related processes in a slow, long-termed fashion. "( Interference of alpha-alkyl-substituted pirinixic acid derivatives with neutrophil functions and signalling pathways.
Greiner, C; Henkel, A; Pergola, C; Poeckel, D; Popescu, L; Rau, O; Schubert-Zsilavecz, M; Werz, O, 2009
)
2.06

Toxicity

ExcerptReferenceRelevance
" Methyl clofenapate was not toxic up to a dose that produced precipitate, so cannot be directly compared with WY, which induced aberrations only at toxic dose levels."( The genetic toxicity of the peroxisome proliferator class of rodent hepatocarcinogen.
Armstrong, MJ; Ashby, J; Galloway, SM; Johnson, TE, 2000
)
0.31
" Due to the adverse effects provoked by hypolipidemic drugs on skeletal muscle function, we also investigated the blocking activity of S-2 and S-4 on skeletal muscle membrane chloride channel conductance and found that these ligands have a pharmacological profile more beneficial compared to fibrates currently used in therapy."( New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
Conte Camerino, D; Fracchiolla, G; Laghezza, A; Lavecchia, A; Loiodice, F; Mazza, F; Montanari, R; Novellino, E; Piemontese, L; Pierno, S; Pochetti, G; Tortorella, P, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"In an effort to develop safe and efficacious compounds for the treatment of metabolic disorders, novel thiophene substituted oxazole containing α-alkoxy-phenylpropanoic acid derivatives are designed as highly potent PPARα/γ dual agonists."( Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Basu, S; Giri, S; Gite, A; Godha, A; Goswami, A; Jain, M; Patel, P; Pingali, H; Raval, P; Raval, S; Shah, M; Suthar, D, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" Despite breaking all the "rule of five" criteria, the dimers had excellent oral bioavailability and pharmacokinetic properties, resulting in good in vivo efficacy in db/db mice."( Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L, 2003
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
" However, a PPARα-agonist (WY14643) failed to regulate the expression of the uncoupling protein 1(UCP1) gene unless combined with retinoic acid."( WY14643 combined with all-trans retinoic acid acts via p38 MAPK to induce "browning" of white adipocytes in mice.
Cui, Y; Ding, J; Li, HR; Sun, GJ; Wang, J; Wang, SJ; Zhang, JX, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" Compound 6 has also shown good oral bioavailability and impressive pharmacokinetic characteristics."( (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
Bajji, AC; Chakrabarti, R; Juluri, S; Kalchar, S; Lohray, BB; Lohray, VB; Mamidi, NV; Misra, P; Padakanti, S; Poondra, RR; Rajagopalan, R; Vikramadithyan, RK, 2001
)
0.31
" Despite breaking all the "rule of five" criteria, the dimers had excellent oral bioavailability and pharmacokinetic properties, resulting in good in vivo efficacy in db/db mice."( Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
Albrektsen, T; Bury, PS; Deussen, HJ; Din, N; Fleckner, J; Frederiksen, KS; Jeppesen, L; Mogensen, JP; Nehlin, J; Pettersson, I; Sauerberg, P; Svensson, LA; Wulff, EM; Ynddal, L, 2003
)
0.32
" c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid 13c exhibited potent hypoglycemic and lipid lowering activity with high oral bioavailability in animal models."( Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Male rats were treated for up to 13 weeks with feed dosed with MPH (HCl salt) at 0, 50, 100, 250, or 1000 ppm or PYR (maleate salt) at 1000 ppm to duplicate the route of administration and high-dose groups used in the carcinogenesis assay."( The hepatocarcinogen methapyrilene but not the analog pyrilamine induces sustained hepatocellular replication and protein alterations in F344 rats in a 13-week feed study.
Anderson, NL; Cunningham, ML; Pippin, LL; Wenk, ML, 1995
)
0.29
" The results provide support for a unified receptor-based mechanism controlling the main PP response, but demonstrate that individual responsive genes can show quite different dose-response curves."( The effects of peroxisome proliferators on protein abundances in mouse liver.
Anderson, NL; Eacho, P; Esquer-Blasco, R; Foxworthy, P; Richardson, F, 1996
)
0.29
" Alterations in hepatic cdk1, cdk2, cdk4, cdk5, and cyclin protein expression were determined in response to acute dosing of the prototypic peroxisome proliferator and hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643)."( Discordant expression of the cyclin-dependent kinases and cyclins in rat liver following acute administration of the hepatocarcinogen [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY14,643).
Babish, JG; Ma, X; Rininger, JA; Wheelock, GD, 1996
)
0.29
" WY14,643 dosing increased concentrations of hepatic proteins of 34- and 37-kDa molecular mass, which were identified through immunoprecipitation as CDK1 and PCNA, respectively."( Discordant hepatic expression of the cell division control enzyme p34cdc2 kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21Waf1 cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimid
Babish, JG; Ma, X; Rininger, JA; Stoffregen, DA; Wheelock, GD, 1997
)
0.3
" In these studies we examined the dose-response relationships for the induction of mRNA for the PPAR-regulated and lipid metabolizing genes ACO, FABP, and CYP4A1 and compared them to the immediate early gene c-myc."( Comparison of dose-response relationships for induction of lipid metabolizing and growth regulatory genes by peroxisome proliferators in rat liver.
Belury, MA; Cunningham, ML; Davis, JW; Moya-Camarena, SY; Snyder, E; Sun, H; Vanden Heuvel, JP, 1998
)
0.3
" Animals were dosed with either vehicle or 100 mg/kg/day WY14,643 by oral gavage for 4 days."( Tumor necrosis factor alpha is not required for WY14,643-induced cell proliferation.
DeLuca, JG; Lawrence, JW; Wollenberg, GK, 2001
)
0.31
" Dose-response studies in the rat showed that the hepatic expression of the polymerase beta and Ref-1 were significantly increased after 6 days of exposure to WY 14,643 at levels of 5 and 50 ppm, respectively."( Hepatic expression of polymerase beta, Ref-1, PCNA, and Bax in WY 14,643-exposed rats and hamsters.
Bingham, CM; Cunningham, ML; Holmes, EW, 2002
)
0.31
" To further our understanding of these processes and to discriminate between different PPAR mediated signalling pathways, a proteomic approach has been undertaken to identify changes in protein expression patterns in Sprague Dawley rat liver following dosing with a PPARalpha agonist (Wyeth 14643), a PPARgamma agonist (Troglitazone) and a compound with mixed PPARalpha/gamma agonist activity (SB-219994)."( Protein expression changes in the Sprague Dawley rat liver proteome following administration of peroxisome proliferator activated receptor alpha and gamma ligands.
Bryant, D; Bugelski, P; Camilleri, P; Cutler, P; Hayes, W; Holbrook, JD; Kramer, K; Lord, PG; Man, WJ; White, IR; Wood, J, 2003
)
0.32
" The two PPAR-alpha activators, fenofibrate and Wy-14643, were dosed at different concentrations in high-fat fed Sprague-Dawley rats, and the transcriptional responses were examined in liver using cDNA microarrays."( Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.
Fleckner, J; Frederiksen, KS; Sauerberg, P; Wassermann, K; Wulf, EM, 2003
)
0.32
" Male Sprague-Dawley rats were dosed with the peroxisome proliferator Wy-14,643 and changes in liver gene expression examined using subtractive suppression hybridisation examined either 12 of 24hr later."( Gene expression changes in rat liver following exposure to liver growth agents: role of Kupffer cells in xenobiotic-mediated liver growth.
Crunkhorn, SE; Gibson, GG; Kramer, K; Lord, PG; Lyon, J; Plant, KE; Plant, NJ, 2004
)
0.32
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" To study the mechanism associated with PFOA toxicity, wild-type and PPARalpha-null mice were orally dosed for 7 days with PFOA (1 or 3 mg/kg) or the PPARalpha agonist Wy14,643 (50 mg/kg)."( Gene profiling in the livers of wild-type and PPARalpha-null mice exposed to perfluorooctanoic acid.
Abbott, BD; Blair, ET; Corton, JC; Das, KP; Lau, C; Rosen, MB; Schmid, JE; Wolf, DC; Wood, CR; Zehr, RD, 2008
)
0.35
" Oral dosing with Wy14643 similarly induced Hilpda mRNA levels in livers of wild-type mice but not Ppara(-/-) mice."( Hypoxia-inducible lipid droplet-associated (HILPDA) is a novel peroxisome proliferator-activated receptor (PPAR) target involved in hepatic triglyceride secretion.
Andasarie, T; De Bosscher, K; Georgiadi, A; Heier, C; Herzig, S; Kersten, S; Krones-Herzig, A; Mattijssen, F; Qi, L; Ratman, D; Szalowska, E; Zechner, R; Zota, A, 2014
)
0.4
" To evaluate the effects of PFHxS and PFNA, male wild-type and Pparα-null mice were dosed by oral gavage with PFHxS (3 or 10mg/kg/day), PFNA (1 or 3mg/kg/day), or vehicle for 7days, and liver gene expression was evaluated by full-genome microarrays."( PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling.
Abbott, B; Corton, JC; Das, KP; Lau, C; Rooney, J; Rosen, MB, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
aryl sulfideAny organic sulfide in which the sulfur is attached to at least one aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (76)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency25.05940.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency54.91413.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency41.42490.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency25.21500.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency25.21500.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency26.15770.000221.22318,912.5098AID743035; AID743036; AID743053; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency29.15370.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency40.88400.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency38.16270.000417.946075.1148AID1346784; AID1346795
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.23660.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency55.23360.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency61.06840.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.58210.000229.305416,493.5996AID743069; AID743075; AID743078
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency28.42330.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency16.09820.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency24.49300.023723.228263.5986AID588543; AID743222; AID743223
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency48.942319.739145.978464.9432AID1159509
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.16230.00207.533739.8107AID891
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency25.11890.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00790.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency35.08050.000627.21521,122.0200AID743202; AID743219
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.30960.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency27.54040.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency6.68240.002319.595674.0614AID651631
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)44.90000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)87.00000.11007.190310.0000AID1443980; AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)0.01000.00032.177410.0000AID412948
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)Ki0.10000.10000.10000.1000AID156230
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.01000.00010.995010.0000AID413191
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)IC50 (µMol)53.70000.00501.205110.0000AID1184305
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)IC50 (µMol)23.20500.00050.82696.3100AID1184298; AID662549
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Ki4.31500.00011.01894.5000AID1673240; AID1680135
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ReninHomo sapiens (human)EC50 (µMol)0.54200.00330.24340.5420AID660302
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)EC50 (µMol)32.00000.00001.262610.0000AID141913
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)32.00000.00000.764610.0000AID141913
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)EC50 (µMol)32.00000.00000.990510.0000AID141913
Cytochrome P450 3A4Homo sapiens (human)EC50 (µMol)0.54200.00010.23283.2000AID660302
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)EC50 (µMol)32.00000.00001.052810.0000AID141913
Cytochrome P450 2C8Homo sapiens (human)EC50 (µMol)0.54200.18500.36350.5420AID660302
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)EC50 (µMol)32.00000.00001.160510.0000AID141913
Retinoic acid receptor RXR-alphaHomo sapiens (human)EC50 (µMol)9.10000.00010.34279.1000AID1614918
Retinoic acid receptor RXR-alphaHomo sapiens (human)Kd1.28000.00040.58388.8000AID1614935
Peroxisome proliferator-activated receptor alphaMus musculus (house mouse)EC50 (µMol)0.47400.00021.397110.0000AID141903; AID1798922; AID240162; AID413011
Retinoic acid receptor RXR-betaHomo sapiens (human)EC50 (µMol)13.00000.00080.52545.2000AID1614919
Delta-type opioid receptorMus musculus (house mouse)EC50 (µMol)4.80000.00110.40144.8000AID365528
Peroxisome proliferator-activated receptor alphaRattus norvegicus (Norway rat)EC50 (µMol)2.10000.16600.86772.2600AID156459
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)EC50 (µMol)29.29640.00000.992210.0000AID1183600; AID156943; AID1614925; AID1798922; AID223547; AID255669; AID307132; AID344819; AID473102; AID91246
Peroxisome proliferator-activated receptor gammaHomo sapiens (human)Kd1.31870.00120.95314.9800AID1440532; AID1614936
Peroxisome proliferator-activated receptor gammaMus musculus (house mouse)EC50 (µMol)32.00000.00031.654210.0000AID141913
Cannabinoid receptor 1Mus musculus (house mouse)EC50 (µMol)0.54200.15850.28110.5420AID660302
Cannabinoid receptor 2Mus musculus (house mouse)EC50 (µMol)0.54200.00730.15460.7040AID660302
Retinoic acid receptor RXR-gammaHomo sapiens (human)EC50 (µMol)31.00000.00010.23801.2250AID1614920
Peroxisome proliferator-activated receptor deltaHomo sapiens (human)EC50 (µMol)45.48670.00020.84609.1000AID156234; AID1614927; AID91241
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)EC50 (µMol)0.04000.00021.848110.0000AID240162
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)8.92690.00061.607410.0000AID1174865; AID1183597; AID1191333; AID1400344; AID1440534; AID1507885; AID1543218; AID156146; AID156218; AID1614917; AID1716436; AID1798922; AID1905820; AID223541; AID240119; AID240121; AID240267; AID255668; AID275787; AID307130; AID365528; AID396052; AID413009; AID439370; AID440652; AID444227; AID610309; AID648525; AID660301; AID660302; AID662543; AID712381; AID722394; AID736344; AID744325; AID744327; AID91237
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Kd0.01890.00100.46862.6000AID1440531
Chloride channel isoform 1 Rattus norvegicus (Norway rat)EC50 (µMol)1.60000.19000.89501.6000AID440652
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (420)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
kidney developmentReninHomo sapiens (human)
mesonephros developmentReninHomo sapiens (human)
angiotensin maturationReninHomo sapiens (human)
renin-angiotensin regulation of aldosterone productionReninHomo sapiens (human)
proteolysisReninHomo sapiens (human)
regulation of blood pressureReninHomo sapiens (human)
male gonad developmentReninHomo sapiens (human)
hormone-mediated signaling pathwayReninHomo sapiens (human)
response to lipopolysaccharideReninHomo sapiens (human)
response to immobilization stressReninHomo sapiens (human)
drinking behaviorReninHomo sapiens (human)
regulation of MAPK cascadeReninHomo sapiens (human)
cell maturationReninHomo sapiens (human)
amyloid-beta metabolic processReninHomo sapiens (human)
response to cAMPReninHomo sapiens (human)
response to cGMPReninHomo sapiens (human)
cellular response to xenobiotic stimulusReninHomo sapiens (human)
juxtaglomerular apparatus developmentReninHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
positive regulation of cholesterol effluxRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of thyroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transporter activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-alphaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-alphaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-alphaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-alphaHomo sapiens (human)
hormone-mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of bone mineralizationRetinoic acid receptor RXR-betaHomo sapiens (human)
mRNA transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-betaHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-betaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-betaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-betaHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of cholesterol effluxPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
long-chain fatty acid transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of osteoblast differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of receptor signaling pathway via STATPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of low-density lipoprotein receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of MAP kinase activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adiponectin secretionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stressPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of connective tissue replacement involved in inflammatory response wound healingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
placenta developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
G protein-coupled receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of blood pressurePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of gene expressionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of lipid storagePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of angiogenesisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
monocyte differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
BMP signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
epithelial cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
response to lipidPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peroxisome proliferator activated receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
glucose homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
mRNA transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipoprotein transportPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
innate immune responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell fate commitmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell maturationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
rhythmic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
white fat cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
lipid homeostasisPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of type II interferon-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of SMAD protein signal transductionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cholesterol transporter activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to low-density lipoprotein particle stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of mitochondrial fissionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
regulation of cellular response to insulin stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of extracellular matrix assemblyPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of miRNA transcriptionPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of cellular response to transforming growth factor beta stimulusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of adipose tissue developmentPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular associated smooth muscle cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell apoptotic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of vascular endothelial cell proliferationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
steroid hormone mediated signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid receptor signaling pathwayRetinoic acid receptor RXR-gammaHomo sapiens (human)
anatomical structure developmentRetinoic acid receptor RXR-gammaHomo sapiens (human)
response to retinoic acidRetinoic acid receptor RXR-gammaHomo sapiens (human)
cell differentiationRetinoic acid receptor RXR-gammaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIRetinoic acid receptor RXR-gammaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (137)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
aspartic-type endopeptidase activityReninHomo sapiens (human)
signaling receptor bindingReninHomo sapiens (human)
insulin-like growth factor receptor bindingReninHomo sapiens (human)
protein bindingReninHomo sapiens (human)
peptidase activityReninHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
vitamin D response element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription cis-regulatory region bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription coregulator bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA-binding transcription factor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-alphaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
enzyme bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
peptide bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
identical protein bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
nuclear vitamin D receptor bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
DNA binding domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
LBD domain bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-betaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-betaHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
transcription cis-regulatory region bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
transcription coregulator bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
double-stranded DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
prostaglandin receptor activityPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
enzyme bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
peptide bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
identical protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nuclear retinoid X receptor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
arachidonic acid bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA binding domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
LBD domain bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
alpha-actinin bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
R-SMAD bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
E-box bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
STAT family protein bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear steroid receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
protein bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
zinc ion bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
molecular condensate scaffold activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
nuclear receptor activityRetinoic acid receptor RXR-gammaHomo sapiens (human)
retinoic acid-responsive element bindingRetinoic acid receptor RXR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular regionReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
plasma membraneReninHomo sapiens (human)
apical part of cellReninHomo sapiens (human)
extracellular spaceReninHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-alphaHomo sapiens (human)
transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
mitochondrionRetinoic acid receptor RXR-alphaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-alphaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-alphaHomo sapiens (human)
receptor complexRetinoic acid receptor RXR-alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaMus musculus (house mouse)
nucleusRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleoplasmRetinoic acid receptor RXR-betaHomo sapiens (human)
nucleolusRetinoic acid receptor RXR-betaHomo sapiens (human)
cytosolRetinoic acid receptor RXR-betaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-betaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-betaHomo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
cytosolPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
intracellular membrane-bounded organellePeroxisome proliferator-activated receptor gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
receptor complexPeroxisome proliferator-activated receptor gammaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor gammaMus musculus (house mouse)
nucleoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
cytoplasmRetinoic acid receptor RXR-gammaHomo sapiens (human)
chromatinRetinoic acid receptor RXR-gammaHomo sapiens (human)
RNA polymerase II transcription regulator complexRetinoic acid receptor RXR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (349)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID156366Binding affinity towards human peroxisome proliferator activated receptor gamma (PPAR gamma) by HTRF assay; Not done2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID1614919Activation of human Gal4-fused RXRbeta LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID440652Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
AID1614932Aqueous solubility of the compound in distilled water after 24 hrs by HPLC analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID440653Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay relative to Wy-146432009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
AID186029Hypolipidemic activity was assessed by measuring liver weight in Sprague-Dawley male rats at 50 mg/kg1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.
AID1431394Agonist activity at full length human N-terminal Myc-tagged PPARalpha expressed in human HepG2 cells coexpressing RXRalpha assessed as transcriptional activation of PPRE at 50 uM incubated for 24 hrs by dual luciferase reporter gene assay2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID396465Inhibition of tube formation in human EAhy926 cells at 10 uM pre-incubated for 12 hrs measured after 24 hrs by phase-contrast microscopy2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
A new antiangiogenic C24 oxylipin from the soft coral Sinularia numerosa.
AID1673224Induction of adipogenesis in human BMMSC cells assessed as increase in HMGCS2 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1597838Upregulation of ACSL1 gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1191335Agonist activity at GAL4-DNA binding domain fused human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID365525Agonist activity at PPARalpha expressed in human HepG2 cells at 10 uM assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID1597818Agonist activity at PPARalpha in human Huh7 cells assessed as PPARA mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID744327Agonist activity at GAL4-fused PPARalpha A454M mutant (unknown origin) expressed in human HepG2 cells by transactivation assay2013European journal of medicinal chemistry, May, Volume: 63Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
AID1440555Agonist activity at PPARalpha in human HepG2 cells assessed as increase in CPT1 protein expression level at 50 uM after 48 hrs by Western blot method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID344822Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay relative to Wy-14,6432008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
AID1901647Agonist activity at human PPARalpha in mouse hepatocytes assessed as induction of cd36 mRNA expression at 50 uM incubated for 16 hrs by quantitative real-time PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1440566Binding affinity to PPARalpha (unknown origin) assessed as kinetic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID156382Transcriptional activation of Peroxisome proliferator-activator receptor (PPAR) alpha expressed in HEK 293T cells at 50 uM2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
AID156619In vitro transactivation of human Peroxisome proliferator activated receptor delta (hPPARdelta)2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID156146In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha)2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1905820Agonist activity at yeast Gal4-fused human PPARalpha LBD transfected in human HepG2 cells assessed as transactivation by measuring beta-galactosidase activity incubated for 20 hrs by luminometry2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID156383Transcriptional activation of Peroxisome proliferator-activator receptor (PPAR) gamma expressed in HEK 293T cells at 1 uM2001Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16
(-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.
AID1440554Agonist activity at PPARalpha in human HepG2 cells assessed as increase in CAC protein expression level at 50 uM after 48 hrs by Western blot method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1901657In vivo agonist activity at human GFP-tagged PPARalpha in transgenic zebrafish assessed as increase in GFP expression in epidermis at 5 uM measured after 14 days by microscopy2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1183600Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
AID1597846Upregulation of ADIPOQ gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID412941Inhibition of PGES1 in human A549 cell microsome assessed as PGE2 formation at 10 uM by cell-free assay relative to control2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1191349Agonist activity at PPARalpha in human HepaR cells assessed as increase in HMGCS2 gene expression at 25 uM incubated for 1 day by quantitative PCR method relative to untreated control2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID307133Agonist activity at human PPARgamma by transactivation assay relative to rosiglitazone2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
Design of potent PPARalpha agonists.
AID1440525Transactivation of GAL4-fused human PPARgamma LBD expressed in human HepG2 cells up to 2 uM after 20 hrs by luciferase reporter gene assay relative to rosiglitazone2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID307135Agonist activity at human PPARdelta by transactivation assay relative to carbacyclin2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
Design of potent PPARalpha agonists.
AID91246Agonist activity for Human PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID91237Agonist activity for Human PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1680133Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of adiponectin mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1673238Binding affinity to PPARgamma (unknown origin) by TR-FRET assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1191334Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay relative to Wy-14,6432015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID1440527Transactivation of GAL4-fused human PPARdelta LBD expressed in human HepG2 cells up to 2 uM after 20 hrs by luciferase reporter gene assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1440565Agonist activity at PPARalpha in human HepG2 cells assessed as increase in mitochondrial mass at 50 uM by CellLight Mitochondria-GFP staining based fluorescent microscopic assay relative to control2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1507888Activation of recombinant human SIRT1 at 10 uM using C-terminal AMC labeled Arg-His-Lys-Lys (Ac) as substrate after 30 mins by FLUOR DE LYS fluorescent assay relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID362898Inhibition of 5-lipoxygenase in human intact polymorphonuclear leukocytes assessed as suppression of A23187-induced product formation at 10 uM2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.
AID156223In vitro transcription activation on human peroxisome proliferator activated receptor-alpha (PPAR alpha)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID240391Effective concentration against human PPARgamma expressed in HepG2 cells; i.a = inactive at tested concentration2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID1680159Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of HMGCR mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1431398Agonist activity at PPARalpha in human THP1 cells assessed as induction of ABCA1 mRNA expression at 50 uM after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID156371In vitro transcriptional activation by human peroxisome proliferator activated receptor-gamma (PPAR gamma); ND= no data2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID256469In vitro activity against human peroxisome proliferator activated gamma/Gal4 in cell-based transactivation assay2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.
AID223549Fold activation relative to maximum activation obtained with rosiglitazone2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1597805Agonist activity at PPARalpha in C57BL/6N mouse primary hepatocytes assessed as activation of Cpt1a mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1614960Activation of human Gal4-fused RXRbeta LBD transfected in HEK293T at 100 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to bexarotene2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1299531Upregulation of FATP2 mRNA level in C57BL mouse small intestine at 0.1% administered through diet for 3 days by RT-PCR analysis2016MedChemComm, Apr-01, Volume: 7, Issue:4
Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.
AID1266114Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth at 100 uM after 48 to 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID156459In vitro transactivation of rat Peroxisome proliferator activated receptor alpha2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID540235Phospholipidosis-negative literature compound
AID712385Agonist activity at human GAL4-fused PPARdelta ligand binding domain expressed in COS-1 cells after 20 hrs by luciferase reporter gene transactivation assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID172946Hypolipidemic activity was assessed by measuring cholesterol in Sprague-Dawley male rats at 50 mg/kg1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.
AID326601Agonist activity at mouse PPARalpha receptor in monkey COS7 cells assessed as activation of CAT reporter gene at 2 uM by transactivation assay relative to Wy,14-6432008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Stereospecific synthesis and bio-activity of novel beta(3)-adrenoceptor agonists and inverse agonists.
AID1614927Activation of human Gal4-fused PPARdelta LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1440532Binding affinity to PPARgamma (unknown origin) assessed as thermodynamic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID412948Inhibition of ovine COX12008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID156363In vitro transcriptional activation by human peroxisome proliferator activated receptor-gamma (PPAR gamma); Inactive2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID113349In vivo nonfasting blood glucose in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID156221Binding affinity towards human peroxisome proliferator activated receptor gamma (PPAR alpha) by HTRF assay; Weakly active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID223543Fold activation relative to maximum hPPAR alpha activation obtained with WY-146432002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID156230Binding affinity towards peroxisome proliferator activated receptor alpha (murinePPAR alpha)2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID660302Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
Discovery of Potent Dual PPARα Agonists/CB1 Ligands.
AID156367Binding affinity towards peroxisome proliferator activated receptor gamma (PPAR gamma); Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID141909Agonist activity for murine PPAR delta receptor in transcriptional activation assay at 100 uM; IA means inactive2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1655132Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID1655128Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID1614933Log D, lipophilicity of the compound by HPLC analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1597825Agonist activity at PPARalpha in C57BL/6N mouse primary hepatocytes assessed as SREBF1 mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1543217Agonist activity at human RXRalpha expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to 9-cis-retinoic acid
AID1785798Agonist activity at human PPARalpha at 10 uM2021ACS medicinal chemistry letters, Nov-11, Volume: 12, Issue:11
Synthesis of 2-Prenylated Alkoxylated Benzopyrans by Horner-Wadsworth-Emmons Olefination with PPARα/γ Agonist Activity.
AID1183601Agonist activity at human PPARgamma LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay relative to pioglitazone2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
AID712381Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID1266120Agonist activity at PPARalpha in human HuH7 cells assessed as increase of fatty acid oxidation by measuring CO2 production using 4C-oleate at 20 uM after 18 hrs by scintillation counting2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID466885Activation of PPARalpha transfected into HEK cells at 10 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID1440568Binding affinity to PPARdelta (unknown origin) assessed as kinetic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID255669In vitro effective concentration against human peroxisome proliferator activated receptor gamma/Gal4 in cell-based transactivation assay2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.
AID156234In vitro transcription activation on human peroxisome proliferator activated receptor-delta (PPAR delta)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID1597840Upregulation of CD36 gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1543218Agonist activity at human PPARalpha expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity by luciferase reporter gene assay relative to WY-14643
AID722379Agonist activity at PPARalpha in human HepG2 cells assessed as upregulation of CPT1 mRNA expression at 50 uM after 24 hrs by RT-PCR analysis relative to control2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
AID1183597Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
AID1901660In vivo agonist activity at human GFP-tagged PPARalpha in transgenic zebrafish assessed as increase in GFP expression in muscle at 5 uM measured after 14 days by microscopy2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID348509Reduction of triglyceride level in Swiss albino mouse serum at 10 mg/kg/day, po for 6 days relative to control2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID466890Activation of PPARalpha transfected into HEK cells at 0.001 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID1614918Activation of human Gal4-fused RXRalpha LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1440533Binding affinity to PPARdelta (unknown origin) assessed as thermodynamic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID344819Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
AID365528Agonist activity at PPARalpha expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID1440561Agonist activity at PPARalpha assessed as induction of positive regulatory loop based receptor transcriptional activation by measuring upregulation of PPARalpha mRNA level in human HepG2 cells at 50 uM after 24 hrs by RT-PCR method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1680129Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of ACAT1 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1680126Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of HMGCR mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID141903Agonist activity for murine PPAR alpha receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1680151Inhibition of UVB-induced MMP1 mRNA in human NHEK cells at 10 uM incubated for 24 hrs by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1633589Ex vivo antiinflammatory activity in Sprague-Dawley rat liver assessed as inhibition of LPS-induced PGE2 production at 1 uM incubated for 4 hrs followed by LPS addition by radioimmunoassay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
AID1543228Anti-inflammatory activity in HUVEC assessed as reduction in TNFalpha-stimulated neutrophil-HUVEC interactions by measuring decrease in neutrophil adhesion to endothelial cells at 1 uM pretreated for 20 hrs before TNFalpha stimulation for 24 hrs using fre
AID1673233Binding affinity to PPARgamma (unknown origin) upto 60 uM by TR-FRET assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID648528Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation at 5 to 10 uM after 20 hrs by beta-galactosidase reporter gene assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
AID662543Transactivation of human PPARalpha expressed in african green monkey CV1 cells by luciferase reporter gene assay2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1901646Agonist activity at human PPARalpha in mouse hepatocytes assessed as induction of fabp1 mRNA expression at 50 uM incubated for 16 hrs by quantitative real-time PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1680158Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of ACACB mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID243412Efficacy against human PPARgamma expressed in HepG2 cells relative to rosiglitazone; i.a = inactive at tested concentration2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID240121Effective concentration for human peroxisome proliferator-activated receptor gamma2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Structure-activity relationships of dimeric PPAR agonists.
AID1597836Upregulation of CEBPA gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID466888Activation of PPARalpha transfected into HEK cells at 0.1 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID141913Agonist activity for murine PPAR gamma receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID1901649Agonist activity at human PPARalpha in mouse hepatocytes assessed as induction of Pdk4 mRNA expression at 50 uM incubated for 16 hrs by quantitative real-time PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1905824Agonist activity at yeast Gal4-fused human PPARdelta transfected in human HepG2 cells assessed as transactivation by measuring beta-galactosidase activity incubated for 20 hrs by luminometry2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID1673247Induction of adipogenesis in human BMMSC cells assessed as increase in ACOX1 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1614917Activation of human Gal4-fused PPARalpha LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1543219Agonist activity at human PPARgamma expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity by luciferase reporter gene assay relative to rosiglitazone
AID1597819Agonist activity at PPARalpha in human Huh7 cells assessed as activation of CPT1A mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID396053Agonist activity at human PPARalpha in U2OS cells by transactivation assay relative to WY-146432008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.
AID184625Evaluated for the dose that causes 50 % lethality in Sprague-Dawley male rats1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.
AID156943In vitro transactivation of human Peroxisome proliferator activated receptor gamma2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID413011Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
AID1680169Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of FASN mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1716439Cytotoxicity against African green monkey COS-1 cells assessed as cell viability at EC50 concentration for PPAR activation assay by XTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
AID1614962Activation of human Gal4-fused PPARalpha LBD transfected in HEK293T at 100 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to GW76472019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1901658In vivo agonist activity at human GFP-tagged PPARalpha in transgenic zebrafish assessed as increase in GFP expression in heart at 5 uM measured after 14 days by microscopy2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1905822Agonist activity at yeast Gal4-fused human PPARgamma transfected in human HepG2 cells assessed as transactivation by measuring beta-galactosidase activity incubated for 20 hrs by luminometry2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID255668In vitro effective concentration against human peroxisome proliferator activated receptor alpha/Gal4 in transactivation assay2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.
AID256468In vitro activity against human peroxisome proliferator activated alpha /Gal4 in cell-based transactivation assay2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.
AID578381Inhibition of mPGES-1 expressed in LPS-stimulated human A549 cells mitochondrial fraction assessed as remaining activity at 10 uM2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold.
AID1291845Agonist activity at PPAR alpha (unknown origin) transfected in HEK293 cells at 1 uM after 24 hrs by dual-luciferase reporter gene assay2016Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity.
AID91241Agonist activity for Human PPAR delta receptor in transcriptional activation assay2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
AID365527Agonist activity at PPARdelta expressed in human HepG2 cells at 10 uM assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1440524Transactivation of GAL4-fused human PPARgamma LBD expressed in human HepG2 cells up to 2 uM after 20 hrs by luciferase reporter gene assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID722380Agonist activity at PPARalpha in human HepG2 cells assessed as upregulation of CAC mRNA expression at 50 uM after 24 hrs by RT-PCR analysis relative to control2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
AID348508Agonist activity at human PPARdelta ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 0.2 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID1614920Activation of human Gal4-fused RXRgamma LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1597821Agonist activity at PPARalpha in human Huh7 cells assessed as SREBF1 mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID413009Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
AID1905821Agonist activity at yeast Gal4-fused human PPARalpha LBD transfected in human HepG2 cells assessed as transactivation by measuring beta-galactosidase activity incubated for 20 hrs by luminometry relative to control2022European journal of medicinal chemistry, May-05, Volume: 235A chemoinformatics search for peroxisome proliferator-activated receptors ligands revealed a new pan-agonist able to reduce lipid accumulation and improve insulin sensitivity.
AID1680172Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of HMGCS2 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1901659In vivo agonist activity at human GFP-tagged PPARalpha in transgenic zebrafish assessed as increase in GFP expression in retina at 5 uM measured after 14 days by microscopy2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID348506Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 10 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID240119Effective concentration for human peroxisome proliferator-activated receptor alpha2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Structure-activity relationships of dimeric PPAR agonists.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID156616In vitro transactivation of human Peroxisome proliferator activated receptor delta (hPPARdelta);Not calculated for transactivation <25% at 30 uM2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID662550Binding affinity to GST-tagged human PPARgamma by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1901648Agonist activity at human PPARalpha in mouse hepatocytes assessed as induction of Fgf21 mRNA expression at 50 uM incubated for 16 hrs by quantitative real-time PCR analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID131596Fasting plasma glucose levels after 30 mg/kg peroral administration in db/db Mouse2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID1174867Agonist activity at human GAL4-PPARgamma ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID552192Agonist activity at human PPARalpha expressed in HepG2 cells co-transfected with PPRE3-TK-luc assessed as beta-galactosidase activity at 10 uM after 20 to 22 hrs by luciferase based transactivation assay relative to control2011Bioorganic & medicinal chemistry, Jan-15, Volume: 19, Issue:2
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
AID191966Hypolipidemic activity was assessed by measuring triglycerides in Sprague-Dawley male rats at 50 mg/kg1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.
AID473102Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
AID365529Agonist activity at PPARgamma expressed in human HepG2 cells assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID1440536Transactivation of GAL4-fused human PPARalpa LBD expressed in human HepG2 cells up to 2 uM after 20 hrs by luciferase reporter gene assay relative to Wy-14,6432017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1431401Agonist activity at PPARalpha in human THP1 cells assessed as induction of CPT1 mRNA expression at 50 uM in presence of MK-886 after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID113348In vivo insulin effect in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1174869Agonist activity at human GAL4-PPARdelta ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID1184305Activation of human PPARgamma ligand binding domain expressed in COS7 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition.
AID1673240Binding affinity to PPARalpha (unknown origin) by TR-FRET assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID396052Agonist activity at human PPARalpha in U2OS cells by transactivation assay2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.
AID1680153Inhibition of UVB-induced PTGS2 mRNA in human NHEK cells at 10 uM incubated for 24 hrs by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID440656Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay relative to rosiglitazone2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
AID260995Effect on PPARalpha transactivation activity in U2OS cells relative to reference2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
AID1597844Upregulation of PLIN1 gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID413274Agonist activity at mouse PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay relative to Wy 14,6432008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
AID1673223Induction of adipogenesis in human BMMSC cells assessed as increase in ACACB mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1191333Agonist activity at GAL4-DNA binding domain fused human PPARalpha ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID1680130Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of FABP4 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1440534Transactivation of GAL4-fused human PPARalpa LBD expressed in human HepG2 cells after 20 hrs by luciferase reporter gene assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1440528Transactivation of GAL4-fused human PPARdelta LBD expressed in human HepG2 cells up to 2 uM after 20 hrs by luciferase reporter gene assay relative to L-165,0412017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1614956Activation of human Gal4-fused RXRalpha LBD transfected in HEK293T at 30 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID156461In vitro transactivation of rat peroxisome proliferator activated receptor alpha2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1543215Agonist activity at human PPARgamma expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to rosiglitazone
AID1901656In vivo agonist activity at human GFP-tagged PPARalpha in transgenic zebrafish assessed as increase in GFP expression in CNS at 5 uM measured after 14 days by microscopy2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1680168Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of SCD1 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID275787Activation of human PPARalpha by GST pull down assay2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.
AID223547In vitro transactivation using receptor transactivation assay against hPPAR gamma2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1299530Downregulation of FATP2 mRNA level in PARP-alpha null C57BL mouse small intestine at 0.1% administered through diet for 3 days by RT-PCR analysis2016MedChemComm, Apr-01, Volume: 7, Issue:4
Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids.
AID240267Effective concentration against human PPARalpha expressed in HepG2 cells2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID223541In vitro transactivation using receptor transactivation assay against hPPAR alpha2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1543214Agonist activity at human PPARalpha expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to WY-14643
AID1633590Ex vivo antiinflammatory activity in Sprague-Dawley rat cortex assessed as inhibition of LPS-induced PGE2 production at 1 uM incubated for 4 hrs followed by LPS addition by radioimmunoassay2019ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
AID1597842Upregulation of FABP4 gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1440551Agonist activity at PPARalpha in human HepG2 cells assessed as increase in CPT1 mRNA level at 50 uM after 24 hrs by RT-PCR method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID660301Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay2011ACS medicinal chemistry letters, Nov-10, Volume: 2, Issue:11
Discovery of Potent Dual PPARα Agonists/CB1 Ligands.
AID307130Agonist activity at human PPARalpha by transactivation assay2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
Design of potent PPARalpha agonists.
AID1440531Binding affinity to PPARalpha (unknown origin) assessed as thermodynamic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID344820Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay relative to rosiglitazone2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
AID1716438Cytotoxicity against African green monkey COS-1 cells assessed as cell viability at EC50 concentration for PPAR activation assay by LDH assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
AID1507885Transactivation of human Gal4-fused PPARalpha LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID439370Agonist activity at human PPARalpha assessed as luciferase activity by transactivation assay2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID1431395Agonist activity at PPARalpha in human THP1 cells assessed as induction of CPT-1 mRNA expression at 50 uM after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID290113Agonist activity at human recombinant PPARalpha at 50 uM by GAL4 transactivation assay relative to control2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Synthesis and evaluation of N-acetyl-L-tyrosine based compounds as PPARalpha selective activators.
AID1673227Induction of adipogenesis in human BMMSC cells assessed as increase in HMGCR mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID240162Effective concentration against murine PPARalpha in transactivation assay2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID1431397Agonist activity at PPARalpha in human THP1 cells assessed as induction of PDK4 mRNA expression at 50 uM after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID712383Agonist activity at human GAL4-fused PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID610309Transactivation of human PPARalpha expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
AID648532Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation at 5 to 10 uM after 20 hrs by beta-galactosidase reporter gene assay relative to pioglitazone2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
AID1183602Agonist activity at human PPARdelta LBD expressed in COS7 cells at 10 uM after 12 hrs by Dual-Glo luciferase assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Molecular determinants for improved activity at PPARα: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARα.
AID1507886Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay relative to rosiglitazone2017European journal of medicinal chemistry, Sep-08, Volume: 137Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID1597850Induction of adipocyte differentiation in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient assessed as lipid accumulation at 25 uM measured for 12 days by Oil red O staining based microscopic analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1614961Activation of human Gal4-fused RXRgamma LBD transfected in HEK293T at 100 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to bexarotene2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1191350Agonist activity at PPARalpha in human HepaR cells assessed as increase in ANGPTL4 gene expression at 25 uM incubated for 1 day by quantitative PCR method relative to untreated control2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID1440567Binding affinity to PPARgamma (unknown origin) assessed as kinetic dissociation constant by SPR assay2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID1611413Transactivation of GAL4-fused human PPARgamma expressed in COS7 cells assessed as efficacy at 10 uM incubated for 24 hrs by luciferase reporter gene assay relative to rosiglitazone2019Bioorganic & medicinal chemistry, 12-15, Volume: 27, Issue:24
Synthesis of benzopyran derivatives as PPARα and/or PPARγ activators.
AID362897Inhibition of 5-lipoxygenase in human intact polymorphonuclear leukocytes assessed as suppression of A23187-induced product formation at 1 uM2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid.
AID1680148Inhibition of UVB-induced PGE2 level in human NHEK cells at 10 uM incubated for 24 hrs by ELISA2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1673239Binding affinity to PPARdelta (unknown origin) by TR-FRET assay2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore.
AID1184298Activation of human PPARalpha ligand binding domain expressed in COS7 cells by luciferase reporter gene assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARα/γ activation and dual 5-LO/mPGES-1 inhibition.
AID1400345Transactivation of GAL4-tagged human PPARalpha LBD expressed in human HepG2 cells after 20 hrs by luciferase reporter gene assay relative to Wy-14,6432018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.
AID156949In vitro transactivation of human Peroxisome proliferator activated receptor gamma2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID156237In vitro transcription activation on human peroxisome proliferator activated receptor-delta (PPAR delta)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID1191351Agonist activity at PPARalpha in human HepaR cells assessed as increase in FABP1 gene expression at 25 uM incubated for 1 day by quantitative PCR method relative to untreated control2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID1431382Agonist activity at GAL4-DBD fused human PPARalpha-LBD (159 to 468 residues) expressed in human HepG2 cells at 10 uM after 24 hrs by dual luciferase reporter gene based mammalian one hybrid assay relative to control2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1614957Activation of human Gal4-fused RXRbeta LBD transfected in HEK293T at 30 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1174865Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells by luciferase reporter gene assay2015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID722375Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in HepG2 cells up to 10 uM after 20 hrs by luciferase reporter gene assay relative to rosiglitazone2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
AID260992Effect on PPARgamma transactivation activity in U2OS cells2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
AID1716436Agonist activity at recombinant human PPARalpha LBD (168 to 468 residues) expressed in African green monkey COS-1 cells incubated for 18 hrs by luciferase reporter gene assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Synthesis and biological evaluations of marine oxohexadecenoic acids: PPARα/γ dual agonism and anti-diabetic target gene effects.
AID1655130Antiproliferative activity against human Capan2 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID1543216Agonist activity at human PPARbeta/delta expressed in African green monkey COS7 cells assessed as increase in receptor transcriptional activity at 10 uM by luciferase reporter gene assay relative to GW501516
AID1597824Agonist activity at PPARalpha in C57BL/6N mouse primary hepatocytes assessed as SCD1 mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1655134Antiproliferative activity against human PTJ86i cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID172463Hypolipidemic activity was assessed by measuring alpha-cholesterol in Sprague-Dawley male rats at 50 mg/kg1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Novel pyrimidine and 1,3,5-triazine hypolipidemic agents.
AID1614938Activation of PPARgamma/RXRalpha in human HepG2 cells assessed as increase in ANGPTL4 mRNA expression at 30 uM after 12 hrs followed by renewal of medium containing test compounds after 6 hrs by PCR analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID115313Area under blood glucose time curve after oral glucose test in mice2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID648525Agonist activity at GAL4-tagged human PPARalpha ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay2012Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6
Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
AID1614958Activation of human Gal4-fused RXRgamma LBD transfected in HEK293T at 30 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1680157Agonist activity at PPARalpha/PPARgamma in human NHEK cells assessed as upregulation of FASN mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID712384Agonist activity at human GAL4-fused PPARgamma ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay relative to rosiglitazone2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID156149In vitro transactivation of human Peroxisome proliferator activated receptor alpha (hPPARalpha)2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID416165Transactivation of mouse recombinant PPARalpha expressed in mouse NIH3T3 cells at 0.1 uM to 10 uM by PPRE activation based dual luciferase reporter gene assay relative to control2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors.
AID113350In vivo nonfasting triglyceride in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1597820Agonist activity at PPARalpha in human Huh7 cells assessed as SCD1 mRNA expression at 50 uM measured after 18 hrs by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1614959Activation of human Gal4-fused RXRalpha LBD transfected in HEK293T at 100 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to bexarotene2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID444227Agonist activity at PPARalpha assessed as receptor transactivation by reporter gene assay2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
AID744325Agonist activity at GAL4-fused PPARalpha (unknown origin) expressed in human HepG2 cells by transactivation assay2013European journal of medicinal chemistry, May, Volume: 63Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
AID1266119Agonist activity at PPARalpha in human HuH7 cells assessed as increase of CPT1alpha expression at 20 uM by Western blotting relative to control2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID348507Agonist activity at human PPARgamma ligand binding domain expressed in human HepG2 cells co-transfected with PPRE3-TK-luc assessed as induction of beta-galactosidase activity at 0.2 uM by transactivation assay2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
AID1680170Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of ACACB mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID1431396Agonist activity at PPARalpha in human THP1 cells assessed as induction of PPARalpha mRNA expression at 50 uM after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1614931Cytotoxicity against human HepG2 cells up to 50 uM after 48 hrs by WST1 assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID115314In vivo insulin effect in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1191336Agonist activity at GAL4-DNA binding domain fused human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation incubated for 20 hrs by luciferase reporter gene assay relative to rosiglitazone2015European journal of medicinal chemistry, Jan-27, Volume: 90Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptor α/γ ligand LT175.
AID736344Agonist activity at human PPARalpha expressed in HEK293 cells cotransfected with PPREx4-TK-luc assessed as activation of luciferase activity measured after 48 hrs by transactivation assay2013Bioorganic & medicinal chemistry, Feb-01, Volume: 21, Issue:3
The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.
AID1174870Agonist activity at human GAL4-PPARdelta ligand binding domain expressed in human HepG2 cells assessed as maximum fold induction by luciferase reporter gene assay relative to rosiglitazone2015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID344821Agonist activity at human PPARalpha ligand binding domain expressed in human HepG2 cells co-transfected with Gal4 by luciferase reporter gene assay2008Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21
Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.
AID156222Binding affinity towards peroxisome proliferator activated receptor alpha (PPAR alpha); Not active2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.
AID243394Efficacy against murine PPARalpha relative to Wy-14,6432005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID1614937Activation of full-length RXRalpha/PPARgamma (unknown origin) transfected in HEK293T cells at 30 uM after 12 to 14 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID578383Inhibition of 5-lipoxygenase in human PMNL assessed as remaining activity at 10 uM2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold.
AID1507889Modulation of SGK1 mRNA expression in HCCD cells at 20 uM after 24 hrs by RT-PCR method relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID1174866Agonist activity at human GAL4-PPARalpha ligand binding domain expressed in human HepG2 cells assessed as maximum fold induction by luciferase reporter gene assay relative to Wy-146432015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID1174868Agonist activity at human GAL4-PPARgamma ligand binding domain expressed in human HepG2 cells assessed as maximum fold induction by luciferase reporter gene assay relative to rosiglitazone2015European journal of medicinal chemistry, Jan-07, Volume: 89Structural development studies of PPARs ligands based on tyrosine scaffold.
AID1655133Antiproliferative activity against human PTJ64i cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID440654Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in human HepG2 cells assessed as receptor transactivation by luciferase reporter gene assay2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
AID722394Transactivation of GAL4-fused human PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
AID712386Agonist activity at human GAL4-fused PPARdelta ligand binding domain expressed in COS-1 cells after 20 hrs by luciferase reporter gene transactivation assay relative to L1650412012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID275788Agonist activity at human PPARalpha expressed in MCF7 cells transfected with co-activator TIF2 by luciferase reporter gene assay at 1 uM2007Journal of medicinal chemistry, Jan-25, Volume: 50, Issue:2
Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.
AID365526Agonist activity at PPARgamma expressed in human HepG2 cells at 0.2 uM assessed as induction of receptor transactivation by reporter gene assay relative to control2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
AID1680167Agonist activity at PPARalpha/PPARgamma in human AT-MSC cells assessed as upregulation of FADS2 mRNA at 10 uM incubated for 3 days by qRT-PCR analysis2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID240120Effective concentration for human peroxisome proliferator-activated receptor delta2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Structure-activity relationships of dimeric PPAR agonists.
AID112794Area under blood glucose time curve after oral glucose test in mice2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID307136Ratio of EC50 for human PPARalpha to human PPARgamma2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
Design of potent PPARalpha agonists.
AID1440550Agonist activity at PPARalpha in human HepG2 cells assessed as increase in CAC mRNA level at 50 uM after 24 hrs by RT-PCR method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID466887Activation of PPARalpha transfected into HEK cells at 1 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID1440562Agonist activity at PPARalpha assessed as induction of positive regulatory loop based receptor transcriptional activation by measuring upregulation of PPARalpha protein expression level in human HepG2 cells at 50 uM after 48 hrs by Western blot method2017European journal of medicinal chemistry, Feb-15, Volume: 127New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.
AID260993Effect on PPARgamma transactivation activity in U2OS cells relative to reference2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
AID1655131Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID1431380Agonist activity at GAL4-DBD fused human PPARalpha-LBD (159 to 468 residues) expressed in human HepG2 cells at 0.5 uM after 24 hrs by dual luciferase reporter gene based mammalian one hybrid assay relative to control2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1614935Binding affinity to recombinant RXRalpha (unknown origin) by isothermal titration calorimetry2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1655129Antiproliferative activity against human BxPC3 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID1680135Binding affinity to human recombinant PPARalpha by Cheng-Prusoff equation based competitive binding TR-FRET assay2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID115316In vivo nonfasting triglyceride in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1431402Agonist activity at PPARalpha in human THP1 cells assessed as induction of PDK4 mRNA expression at 50 uM in presence of MK-886 after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1614925Activation of human Gal4-fused PPARgamma LBD transfected in HEK293T after 14 to 16 hrs by dual-glo luciferase reporter gene assay2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID712382Agonist activity at human GAL4-fused PPARalpha ligand binding domain expressed in HepG2 cells after 20 hrs by luciferase reporter gene transactivation assay relative to WY146432012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.
AID413191Inhibition of human recombinant COX22008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase.
AID1431400Agonist activity at PPARalpha in human THP1 cells assessed as induction of PPARalpha mRNA expression at 50 uM in presence of MK-886 after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1614936Binding affinity to recombinant PPARgamma (unknown origin) by isothermal titration calorimetry2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID413010Agonist activity at human PPARalpha ligand binding domain expressed in human Hep G2 cells co-transfected with Gal4-DBD by luciferase reporter gene assay relative to Wy 14,6432008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
AID1614963Activation of human Gal4-fused PPARgamma LBD transfected in HEK293T at 100 uM after 14 to 16 hrs by dual-glo luciferase reporter gene assay relative to rosiglitazone2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID722377Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in HepG2 cells up to 10 uM after 20 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Jan-10, Volume: 56, Issue:1
New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptor α/γ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.
AID1400344Transactivation of GAL4-tagged human PPARalpha LBD expressed in human HepG2 cells after 20 hrs by luciferase reporter gene assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.
AID1431403Agonist activity at PPARalpha in human THP1 cells assessed as induction of ABCA1 mRNA expression at 50 uM in presence of MK-886 after 24 hrs by RT-qPCR analysis2016Journal of natural products, Dec-23, Volume: 79, Issue:12
Identification of Picrasidine C as a Subtype-Selective PPARα Agonist.
AID1507887Transactivation of human Gal4-fused PPARgamma LBD expressed in African green monkey COS7 cells after 24 hrs by luciferase reporter gene assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Anti-diabetic activity of fused PPARγ-SIRT1 ligands with limited body-weight gain by mimicking calorie restriction and decreasing SGK1 expression.
AID243395Efficacy against human PPARalpha expressed in HepG2 cells relative to Wy-14,6432005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
AID1655135Antiproliferative activity against human A498 cells assessed as inhibition of cell growth at 75 uM incubated for 72 hrs by MTT assay relative to control2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies.
AID260994Effect on PPARalpha transactivation activity in U2OS cells2006Bioorganic & medicinal chemistry letters, Feb-15, Volume: 16, Issue:4
Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists.
AID578385Inhibition of human recombinant 5-lipoxygenase assessed as remaining activity at 10 uM2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold.
AID1614940Activation of RXR in human HepG2 cells assessed as increase in ApoE mRNA expression at 30 uM after 12 hrs followed by renewal of medium containing test compounds after 6 hrs by PCR analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID473103Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay relative to pioglitazone2010Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8
Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID307132Agonist activity at human PPARgamma by transactivation assay2007Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11
Design of potent PPARalpha agonists.
AID1614934Metabolic stability in Sprague-Dawley rat liver microsomes assessed as remaining parent compound level at 10 uM preincubated for 5 mins with NADPH generating system followed by liver microsomes addition and measured after 60 mins by HPLC analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation.
AID1266113Cytotoxicity against human HEK293 cells assessed as inhibition of cell growth at 50 uM after 48 to 72 hrs by MTT assay2015Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24
Identification of dual PPARα/γ agonists and their effects on lipid metabolism.
AID156218In vitro transcription activation on human peroxisome proliferator activated receptor-alpha (PPAR alpha)2004Bioorganic & medicinal chemistry letters, Jul-05, Volume: 14, Issue:13
Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
AID662549Binding affinity to GST-tagged human PPARalpha by TR-FRET analysis2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
Total synthesis and dual PPARα/γ agonist effects of amorphastilbol and its synthetic derivatives.
AID1597848Upregulation of ANGPTL4 gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID1597834Upregulation of PPARgamma gene expression in human preadipocyte derived from Simpson-Golabi-Behmel syndrome (SGBS) patient at 25 uM measured for 12 days by qRT-PCR analysis2019Bioorganic & medicinal chemistry, 09-15, Volume: 27, Issue:18
Molecular modelling, synthesis, and biological evaluations of a 3,5-disubstituted isoxazole fatty acid analogue as a PPARα-selective agonist.
AID466889Activation of PPARalpha transfected into HEK cells at 0.01 uM by luciferase assay2010Journal of natural products, Jan, Volume: 73, Issue:1
Iridoids from Fraxinus excelsior with adipocyte differentiation-inhibitory and PPARalpha activation activity.
AID610311Transactivation of human PPARgamma expressed in human HepG2 cells co-transfected with PPRE3-TK-Luc by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
AID115315In vivo nonfasting blood glucose in db/db mice after oral treatment2003Journal of medicinal chemistry, Nov-06, Volume: 46, Issue:23
Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.
AID1680147Inhibition of UVB-induced MMP1 level in human NHEK cells at 10 uM incubated for 24 hrs by ELISA2018Bioorganic & medicinal chemistry, 11-15, Volume: 26, Issue:21
Kojyl cinnamate esters are peroxisome proliferator-activated receptor α/γ dual agonists.
AID223546Fold activation relative to maximum activation obtained with carbacyclin2002Journal of medicinal chemistry, Feb-14, Volume: 45, Issue:4
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.
AID1798922Cell-Based Transcription Assay from Article 10.1021/jm800733h: \\Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket coul2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346733Human Peroxisome proliferator-activated receptor-alpha (1C. Peroxisome proliferator-activated receptors)2000Journal of medicinal chemistry, Feb-24, Volume: 43, Issue:4
The PPARs: from orphan receptors to drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (845)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (4.73)18.7374
1990's164 (19.41)18.2507
2000's414 (48.99)29.6817
2010's201 (23.79)24.3611
2020's26 (3.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.94 (24.57)
Research Supply Index6.77 (2.92)
Research Growth Index5.07 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.23%)5.53%
Reviews15 (1.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other848 (98.03%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]